In a law-changing move, the Michigan Senate has taken considerable action against the long-standing law facet that has been granting immunity to pharmaceutical manufacturers and sellers from product liability lawsuits. This law, historically, has shielded companies producing pharmaceutical products that have been approved by the U.S. Food and Drug Administration (FDA) from any legal fallout.
The bill was recently passed in the Senate, marking a significant shift in legislative attitudes towards pharma companies and their responsibility towards consumers, could lead to a substantial increase in product liability suits, particularly within the state of Michigan. The ripple effects of such a legislative move may inspire more aggressive oversight in other states and federally, particularly in the wake of increasing scrutiny of the pharma industry.
According to global law firm Jones Day, this could potentially have wide-reaching implications for pharmaceutical companies, not just within Michigan but also potentially outside of the state’s boundaries, depending on the precedents set and the reactions of other state legislatures.
As an important consumer protection measure, product liability lawsuits provide a legal recourse for customers that have been harmed by faulty products. The repeal of this immunity for pharmaceutical companies recognized by the FDA points to a larger trend of accountability for companies, as observed in various sectors worldwide.
For further information on the legislative change and its implications, see the article published on JD Supra.